Gonorrhea Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Gonorrhea is a sexually transmitted disease (STD) caused by the Neisseria gonorrhoeae bacterium. It can infect both males and females. The bacteria target the cells of the mucous membranes including surfaces of the urethra, vagina, cervix, and endometrium, lining of the eyelid, the throat, and fallopian tubes. Symptoms include painful urination, pus-like discharge from the penis, increased vaginal discharge, abdominal pain, and pelvic pain. Treatment includes antibiotics.
The Gonorrhea drugs in development market research report provide comprehensive information on the therapeutics under development for Gonorrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Gonorrhea and features dormant and discontinued products.
Key Targets in the Gonorrhea Pipeline Products Market
The key targets in the Gonorrhea pipeline products market include DNA Gyrase, DNA Topoisomerase IV, 23S Ribosomal RNA, 16S Ribosomal RNA, and others.
Gonorrhea Pipeline Products Analysis Market by Targets
For more target insights, download a free report sample
Key Mechanisms of Action in the Gonorrhea Pipeline Products Market
The key mechanisms of action in the Gonorrhea pipeline products market include DNA Gyrase Inhibitor, DNA Topoisomerase IV Inhibitor, 23S Ribosomal RNA Inhibitor, 16S Ribosomal RNA Inhibitor, and others.
Gonorrhea Pipeline Products Market Analysis by Mechanism of Actions
For more mechanism of actions insights, download a free report sample
Key Routes of Administration in the Gonorrhea Pipeline Products Market
The key routes of administration in the Gonorrhea pipeline products market include oral, intravenous, topical, nasal, and others.
Gonorrhea Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Gonorrhea Pipeline Products Market
The key molecule types in the Gonorrhea pipeline products market include small molecule, vaccine, biologic, fusion protein, and others.
Gonorrhea Pipeline Products Market Analysis by Molecule Type
For more molecule type insights, download a free report sample
Major Companies in the Gonorrhea Pipeline Products Market
Some of the major companies in the Gonorrhea pipeline products market are Microbiotix Inc, TherapyX Inc, Biolytics Pharma, Boulos and Cooper Pharmaceuticals Pty Ltd, and Debiopharm International SA.
Gonorrhea Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
Market Report Overview
| Key targets | DNA Gyrase, DNA Topoisomerase IV, 23S Ribosomal RNA, 16S Ribosomal RNA, and Others |
| Key mechanism of action | DNA Gyrase Inhibitor, DNA Topoisomerase IV Inhibitor, 23S Ribosomal RNA Inhibitor, 16S Ribosomal RNA Inhibitor, and Others |
| Key routes of administration | Oral, Intravenous, Topical, Nasal, and Others |
| Key molecule type | Small Molecule, Vaccine, Biologic, Fusion Protein, and Others |
| Major companies | Microbiotix Inc, TherapyX Inc, Biolytics Pharma, Boulos and Cooper Pharmaceuticals Pty Ltd, and Debiopharm International SA |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Gonorrhea (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Gonorrhea (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gonorrhea (Infectious Disease) therapeutics and enlists all their major and minor products for the indication.
- The pipeline guide evaluates Gonorrhea (Infectious Disease) therapeutics based on their mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline products.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Gonorrhea (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gonorrhea (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies in the Gonorrhea (Infectious Disease) market.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the Gonorrhea (Infectious Disease) pipeline’s depth and the focus of therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued products and apply this knowledge to pipeline development.
Boulos and Cooper Pharmaceuticals Pty Ltd
Debiopharm International SA
Entasis Therapeutics Holdings Inc
GlaxoSmithKline Plc
Hsiri Therapeutics LLC
Melinta Therapeutics Inc
Merck & Co Inc
Microbiotix Inc
Nabriva Therapeutics Plc
Pharmiva AB
Redx Pharma Plc
TherapyX Inc
Yaso Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Gonorrhea pipeline products market?
The key targets in the Gonorrhea pipeline products market include DNA Gyrase, DNA Topoisomerase IV, 23S Ribosomal RNA, 16S Ribosomal RNA, and others.
-
What are the key mechanisms of action in the Gonorrhea pipeline products market?
The key mechanisms of action in the Gonorrhea pipeline products market include DNA Gyrase Inhibitor, DNA Topoisomerase IV Inhibitor, 23S Ribosomal RNA Inhibitor, 16S Ribosomal RNA Inhibitor, and others.
-
What are the key routes of administration in the Gonorrhea pipeline products market?
The key routes of administration in the Gonorrhea pipeline products market include oral, intravenous, topical, nasal and others.
-
What are the key molecule types in the Gonorrhea pipeline products market?
The key molecule types in the Gonorrhea pipeline products market include small molecule, vaccine, biologic, fusion protein, and others.
-
Which are the major companies in the Gonorrhea pipeline products market?
Some of the major companies in the Gonorrhea pipeline products market are Microbiotix Inc, TherapyX Inc, Biolytics Pharma, Boulos and Cooper Pharmaceuticals Pty Ltd, and Debiopharm International SA.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Infectious Disease reports